Canada recommends public funding for Alzheimer’s drug Leqembi
Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The reco
<p>Biogen Inc. stock drew renewed attention after a Canadian advisory committee issued a final positive recommendation supporting public reimbursement of Leqembi, developed with partner Eisai, for Canadians with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. The reco</p>